TECHMODAL LIMITED

Here is a comprehensive financial health assessment for Techmodal Limited, using a diagnostic approach to evaluate the company's vital signs and overall condition.

1. Financial Health Score: F

Explanation: The patient has suffered a fatal cardiac event. Despite showing a clean bill of health during its last detailed financial examination (2019), the company's current status is Liquidation. No amount of historical vitality can alter the fact that the business is currently undergoing a formal wind-down process.

2. Key Vital Signs (Based on 2019 Data)

• Blood Pressure (Cash Flow & Liquidity): In 2019, the company's blood pressure was excellent. Cash at bank was £1.41 million, and net current assets (working capital) were a robust £2.8 million. The circulatory system appeared highly functional and capable of meeting short-term obligations.
• Immune System (Net Assets & Equity): Shareholders' funds stood at £2.97 million in 2019, up from £1.56 million the previous year. The company had a strong financial buffer to fight off external shocks.
• Cholesterol Levels (Debt & Liabilities): Total liabilities were £2.49 million, comfortably covered by total assets of £5.69 million. However, trade debtors swelled to £3.88 million (up from £1.95 million), representing a potential blockage in the arteries if invoices were not collected on time.
• Heart Rate (Growth & Activity): The average employee count jumped from 65 to 97 in a single year, indicating a rapid heart rate, aggressive expansion, and increased operational strain.

3. Diagnosis

Symptoms Analysis: The 2019 accounts reveal a business experiencing hyper-growth. While retained earnings (profit) increased by over £1.4 million, the balance sheet shows symptoms of overtrading. Accrued expenses more than doubled to over £1 million, and the debtor book ballooned. This suggests that while revenue was being recognized, the cash conversion cycle was lengthening, putting strain on the company's operational veins.

Overall Condition: Terminal. The company is currently in Liquidation. The dramatic transition from a highly profitable, cash-rich entity in 2019 to a liquidation status today suggests a catastrophic event occurred post-2019. This could have been a sudden loss of a critical contract (a severe blow to the head), a strategic restructuring by its parent company, BAE Systems (an elective termination), or a catastrophic failure to collect on the massive 2019 debtor book, leading to cash flow asystole.

4. Recommendations

• For the Patient (The Company): As the company is in Liquidation, revival is no longer an option. The focus must shift entirely to a compliant and orderly wind-down.
• For the Directors (Attending Physicians): Ensure all company records, banking, and statutory documents are preserved and handed over to the appointed liquidator. Directors must cooperate fully with the insolvency practitioner to ensure compliance with statutory duties and avoid any accusations of wrongful trading.
• For Creditors (Blood Supply): Submit all outstanding claims to the liquidator promptly. Given the historically strong asset base in 2019, there may be a recovery dividend, though the sudden collapse makes the final realization uncertain.
• Preventative Medicine for Others: Businesses experiencing rapid growth must monitor debtor days aggressively. A swollen debtor book is a common prelude to cash flow failure, even when the income statement looks healthy. Regular "check-ups" on cash conversion are vital during expansion.